Literature DB >> 31522999

A Targeted Protein Degradation Cell-Based Screening for Nanobodies Selective toward the Cellular RHOB GTP-Bound Conformation.

Nicolas Bery1, Laura Keller2, Marjorie Soulié1, Rémi Gence1, Anne-Laure Iscache2, Julia Cherier2, Stéphanie Cabantous1, Olivier Sordet1, Isabelle Lajoie-Mazenc1, Jean-Denis Pedelacq3, Gilles Favre4, Aurélien Olichon5.   

Abstract

The selective downregulation of activated intracellular proteins is a key challenge in cell biology. RHO small GTPases switch between a guanosine diphosphate (GDP)-bound and a guanosine triphosphate (GTP)-bound state that drives downstream signaling. At present, no tool is available to study endogenous RHO-GTPinduced conformational changes in live cells. Here, we established a cell-based screen to selectively degrade RHOB-GTP using F-box-intracellular single-domain antibody fusion. We identified one intracellular antibody (intrabody) that shows selective targeting of endogenous RHOB-GTP mediated by interactions between the CDR3 loop of the domain antibody and the GTP-binding pocket of RHOB. Our results suggest that, while RHOB is highly regulated at the expression level, only the GTP-bound pool, but not its global expression, mediates RHOB functions in genomic instability and in cell invasion. The F-box/intrabody-targeted protein degradation represents a unique approach to knock down the active form of small GTPases or other proteins with multiple cellular activities.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  RAS-related RHO-GTPases; RHOB; cell migration; cell-based screen; genomic instability; intrabody; nanobody; protein interference; targeted protein degradation

Year:  2019        PMID: 31522999     DOI: 10.1016/j.chembiol.2019.08.009

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  14 in total

Review 1.  Exploring cellular biochemistry with nanobodies.

Authors:  Ross W Cheloha; Thibault J Harmand; Charlotte Wijne; Thomas U Schwartz; Hidde L Ploegh
Journal:  J Biol Chem       Date:  2020-08-31       Impact factor: 5.157

2.  A Cell-based Screening Method Using an Intracellular Antibody for Discovering Small Molecules Targeting Hard-to-drug Proteins.

Authors:  Nicolas Bery; Terry H Rabbitts
Journal:  Bio Protoc       Date:  2022-02-20

Review 3.  Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.

Authors:  Congcong Zhang; Rina M Ötjengerdes; Julian Roewe; Rebeca Mejias; Andrea L J Marschall
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

4.  A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS.

Authors:  Nicolas Bery; Ami Miller; Terry Rabbitts
Journal:  Nat Commun       Date:  2020-06-26       Impact factor: 14.919

Review 5.  Prey for the Proteasome: Targeted Protein Degradation-A Medicinal Chemist's Perspective.

Authors:  Laura M Luh; Ulrike Scheib; Katrin Juenemann; Lars Wortmann; Michael Brands; Philipp M Cromm
Journal:  Angew Chem Int Ed Engl       Date:  2020-07-30       Impact factor: 15.336

Review 6.  Targeted Protein Degradation Tools: Overview and Future Perspectives.

Authors:  Yuri Prozzillo; Gaia Fattorini; Maria Virginia Santopietro; Luigi Suglia; Alessandra Ruggiero; Diego Ferreri; Giovanni Messina
Journal:  Biology (Basel)       Date:  2020-11-26

Review 7.  An Inside Job: Applications of Intracellular Single Domain Antibodies.

Authors:  Eline Soetens; Marlies Ballegeer; Xavier Saelens
Journal:  Biomolecules       Date:  2020-12-12

8.  Protocol to select conformation-specific intracellular antibodies for targeted protein degradation in an engineered cell line.

Authors:  Nicolas Bery; Gilles Favre; Aurélien Olichon
Journal:  STAR Protoc       Date:  2020-12-30

9.  Creating a Selective Nanobody Against 3-Nitrotyrosine Containing Proteins.

Authors:  Elise M Van Fossen; Sonia Grutzius; Carl E Ruby; Dan V Mourich; Chris Cebra; Shay Bracha; P Andrew Karplus; Richard B Cooley; Ryan A Mehl
Journal:  Front Chem       Date:  2022-02-21       Impact factor: 5.221

Review 10.  Progress in the therapeutic inhibition of Cdc42 signalling.

Authors:  Natasha P Murphy; Helen R Mott; Darerca Owen
Journal:  Biochem Soc Trans       Date:  2021-06-30       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.